Posted by Michael Wonder on 17 Oct 2025
Tezspire approved in the US for chronic rhinosinusitis with nasal polyps
17 October 2025 - AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps, a complex epithelial-driven inflammatory condition.
Tezspire is the first and only biologic that targets thymic stromal lymphopoietin to be approved for chronic rhinosinusitis with nasal polyps.
